Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967733 | 0.81 | CNR2 (0.41) | ALDH1A1CYP3A4TSHRRECQLGAA | |
| SCHEMBL670632 | 0.81 | DTYMK (0.36) | ALDH1A1CYP3A4TSHRLMNAXDH | |
| SCHEMBL672138 | 0.80 | PDGFRB (0.41) | ALDH1A1CYP1A2MAPTLMNASMN1; SMN2 | |
| SCHEMBL2983072 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP3A4TSHRRECQL | |
| SCHEMBL28825412 | 0.71 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP3A4TSHRRECQL | |
| SCHEMBL23620106 | 0.70 | TDP1 (0.37) | ALDH1A1CYP1A2CYP3A4TSHRRECQL | |
| SCHEMBL25637795 | 0.69 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP3A4TSHRRECQL | |
| SCHEMBL20516243 | 0.69 | NPC1 (0.32) | ALDH1A1CYP1A2CYP3A4TSHRRECQL | |
| SCHEMBL18702635 | 0.69 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRRECQLMAPT | |
| SCHEMBL29502898 | 0.69 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRRECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781452-B2 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781452-B2 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781452-B2 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| EP-1737862-A4 | IMIDAZOPYRIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1737862-A1 | IMIDAZOPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20050272764-A1 | Imidazopyridine compound | EISAI CO., LTD. | 2005-12-08 | — | — | US | disclosed |
| WO-2005103049-A1 | IMIDAZOPYRIDINE COMPOUND | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272764-A1 | Imidazopyridine compound | H1-3, KCNH2, H1-4 | ALDH1A1 389/4885CYP1A2 331/4885CYP3A4 230/4885 |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | HRH2, HRH4, GRPR | ALDH1A1 710/4885CYP1A2 1413/4885CYP3A4 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.